PTO/SB/08A (07-05)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

03/30/2008

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of

(Podnov Swartz)

Sheet

Application Number 10/542,958 Filing Date January 23, 2004 (I.A.) First Named Inventor William R. Jacobs, Jr. not yet determined Art Unit net yet determined Swartz Examiner Name

Attorney Docket Number 96700/1031

U. S. PATENT DOCUMENTS Publication Date MM-DD-YYYY Name of Patentee or Pages, Columns, Lines, Where Document Number No Applicant of Cited Document Relevant Passages or Relev Number-Kind Code² (# Answer Figures Appear 7RS/ US- 6.221,365 B1 1 04-24-2001 Kevin F. Jones /RS/ 2 ^{US-} 5,955,077 09-21-1999 Peter Anderson et al. US- 6,271,034 B1 08-07-2001 S. Bardarov and W.R Jacobs, Jr. US-HS. USus-US-US-US-US-115. US-US-

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ "Number 4" Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T6				
/RS/	4	WO 03/070164 A2	08-28-2003	Jacobs, Jr. et al.						
						F				

0.5.10.00	middio ondres	Contracted	00,00,200
	Initial if reference considered, whether or not citation is in conformance with MPEP		
	Include copy of this form with next communication to applicant. Applicant's unique of		
	lent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the di		

Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Institution a statistical for information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confideritality is governed by 38 U.SC. 122 and 37 CFR 1.14. This collection is estimated to last a Very to complete, including principle, preparing, and summitting the completed application from the USFTO. There will very depending upon the individual case, and you comments on the amount of time you require to complete this form and/or suppositions for individual case. A very depending upon the individual case, and a very comments on the amount of time you require to complete this form and/or supposition for more than a very depending upon the individual case. A very comments on the amount of time you require to complete this form and/or supposition for more than a very depending upon the individual case. A very comments on the amount of time you require to complete this form and/or supposition for the property of the very depending upon the individual case. A very comments on the property of the public very depending upon the individual case. A very comments on the property of the public very depending upon the individual case. A very comments on the property of the public very depending upon the individual case. A very comments of the property of the public very depending upon the individual case. A very comments of the property of the public very depending upon the individual case. A very comments of the public very depending upon the individual case. A very depending upon th TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

linder the Panerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Cubadha	Substitute for form 1449/PTO			Complete if Known		
Substitute for total 1445F 10				Application Number	10/542,958	
INFO	RMATION	DIS	CLOSURE	Filing Date	January 23, 2004 (I.A.)	
STA	STATEMENT BY APPLICANT			First Named Inventor	William R. Jacobs, Jr.	
				Art Unit	not yet determined 1645	
(Use as many sheets as necessary)			scessary)	Examiner Name	not yet determined Swartz	
Sheet	2	of	5	Attorney Docket Number	96700/1031	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/RS/	5	ANDERSEN, P., "Host Responses and Antigens Involved in Protective Immunity to Mycobacterium tuberculosis"; Scand. J. Immunol. 1997, pp.115-31, Vol. 45.	
/RS/	6	ANDERSEN, P., et al., "Proteins Released from Mycobacterium tuberculosis during Growth"; Infection and Immunity, June 1991, pp. 1905-10, Vol. 59, No. 6.	
/RS/	7	BEHR, M.A., et al., "Comparative Genomics of BCG Vaccines by Whole-Genome DNA Microarray"; Science, May 28, 1999, pp. 1520-23, Vol. 284.	
/RS/	8	CAMACHO, L.R., et al., "Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis"; Molecular Microbiology, 1999, pp. 257-67, Vol. 34.	
/RS/	9	CHAMBERS, M.A., et al., "Identification of a Mycobacterium bovis BCG Auxotrophic Mutant That Protects Guinea Pigs against M. bovis and Hematogenous Spread of Mycobacterium tuberculosis without Sensitization to Tuberculinit," Infection and Immunity, Dec. 2000, pp. 7084-99, Vol. 68, No. 12.	
/RS/	10	COLE, S.T., et al., "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence", Nature, June 11, 1998, pp. 537-44 + table pages, Vol. 393.	
/RS/	11	COX, J., et al., "Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice"; Nature, Nov. 4, 1999, pp. 79-83, Vol. 402.	
/RS/	12	DASCHER C.C. et al., "Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis"; International Immunology, Aug. 2003, pp. 915-25, Vol. 15, No. 8.	
/RS/	13	DE VOSS, J.J., et al. "The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages"; PNAS, Feb. 1, 2000, pp. 1252-57, Vol. 97, No. 3.	
/RS/	14	GLICKMAN, M.S., et al., "The Mycobacterium tuberculosis cmaA2 Gene Encodes a Mycolic Acid trans-Cyclopropane Synthetaser", The Journal of Biological Chemistry, Jan. 19, 2001, pp. 2228-33, Vol. 276, No. 3.	

Examiner Signature	/Rodney Swartz/	Date Considered	03/30/2008
*EYAMINED: I	vitel if reference considered whether or not citation is in conformance with MPEP 60	9 Draw line through o	tation if not in conformance and not

Date

Examiner

considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicants vinige claims designation manther (cplonal) 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.38. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confiderable by governed by 35 USC. 122 and 37 CFR 1.14. This collection is estimated to also 2 hours to complete, including gathering, preparing, and submitting the completed application from the USPTO. Then will very depending upon the individual case, Any comments on the amount of alm by un require to complete this form and/or augustions for reducing this burden, should be sent to the Chef information Office, 10.3. Patient and Trademan Critice, P.O. Sent 1400, Abscandin, VA 22313-4450, DOT SRID TESS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patients, P.O. Sox 1400, Abscandin, VA 22313-4450, DOT SRID TESS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

Und	er the Paperwork Red	uction A	t of 1995, no persons ar		of information unless it contains a valid OMB control number.	
Substitut	e for form 1449/PTO			Complete if Known		
				Application Number	10/542,958	
			CLOSURE	Filing Date	January 23, 2004 (I.A.)	
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	William R. Jacobs, Jr.	
				Art Unit	not yet determined 1645	
	(auc au many and			Examiner Name	net-yet determined Swartz	
Sheet	3	of	5	Attorney Docket Number	96700/1031	

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cily and/or country where published.	T ²				
/RS/	15	GORDON, S.V., et al., "Genomics of Mycobacterium bovis"; Tuberculosis, 2001, pp. 157-63, Vol. 81(1/2).					
/RS/	16	GULERIA, I., et al., "Auxotrophic vaccines for tuberculosis"; Nature Medicine, March 1996, pp. 334-37, Vol. 2, No. 3.					
/RS/	17	HARBOE M. et al., "Evidence for Occurance of the ESAT-6 Protein in Mycobacterium tuberculosis and Virulent Mycobacterium bovis and for its Absence in Mycobacterium bovis BCG"; Infection and Immunity, Jan. 1996, pp 16-2					
/RS/	18	HERNANDEZ-PANDO R. et al., "Pathogenesis of Tuberculosis in Mice Exposed to Low and High Doses of an Environmental Mycobacterial Saprophtye before Infection"; Infection and Immunity, Aug. 1997, pp. 3317-27, Vol. 65, No. 8.					
/RS/	19	HONDALUS, M.K., et al., "Attenuation of and Protection Induced by a Leucine Auxotroph of Mycobacterium tuberculosis"; Infection and Immunity, May 2000, pp. 2888-98, Vol. 68, No. 5.					
/RS/	20	HSU, T., et al., "The primary mechanism of attenuation of bacillus Calmette-Guérin is a loss of secreted tylic function required for invasion of lung interstitial tissue"; PNAS, October 2003, pp. 1240-25, Vol. 100, No. 21.					
/RS/	21	JACKSON, M., et al., "Persistence and Protective Efficacy of a Mycobacterium tuberculosis Auxotroph Vaccine"; Infection and Immunity, June 1999, pp. 2867-73, Vol. 67, No. 6.					
/RS/	22	LADEL, C.H., et al., "Immune response to Mycobacterium bovis bacille Calmette Guérin infection in major histocompatibility complex class I and III-deficient knock-out nieue: contribution of CD4 and CD8 T cells to acquired resistance"; Eur. J. Immunol., 1995, pp. 377-384, Vol. 25.					
/RS/	23	MAHAIRAS, G.G., et al., "Molecular Analysis of Genetic Differences between Mycobacterium bovis BCG an Virulent M. bovis"; Journal of Bacteriology, March 1996, pp. 1274-82, Vol. 178, No. 5.					
/RS/	24	MANCA, C., et al., "Virulence of a Mycobacterium tuberculosis clinical Isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/erba"; PNAS, May 8, 2001, pp. 752-57, Vol 98, No. 10.					

Examiner Signature	/Rodney Swartz/	Date Considered	03/30/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{**}EXAMINE** Initial Infelimental comparing whether or not claims in conformance with MPEP 500. Draw line through clatton if not in conformance and not a "Applicant's turbine or claims designation number (pollous). **Explained is turbine, and exhibit hargonize Trainable in statistical. **Applicant is turbined. **Explained is provided by 30 CFR 1.96. The information is nequired to obtain or retain a benefit by the public which is to file (and by the USP1O process) an applicant to conformation is estimated to be and hours to complete, including to process) an application. Confidentiality is governed by 30 LGR 1.02 and 37 CFR 1.41. This collection is estimated to be all hours to complete, including to process) and application. Confidentiality is governed by 30 LGR 1.02 and 30 CFR 1.02 and 30 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	ler the Papenvork Red e for form 1449/PTO	uction Ac	t of 1995, no persons ar	e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Substitut	e 101 101111 1449/P1O			Application Number	10/542,958		
			CLOSURE	Filing Date	January 23, 2004 (I.A.)		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	William R. Jacobs, Jr.		
(Use as many sheets as necessary)				Art Unit	not yet determined 1645		
,,				Examiner Name	not yet determined Swartz		
Sheet	4	of	5	Attorney Docket Number	96700/1031		

		NON PATENT LITERATURE DOCUMENTS	-
Examiner Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ilem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cily and/or country where published.	T ²
/RS/	25	MCKINNEY, J.D., et al., "Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase", Nature, Aug. 17, 2000, pp. 735-38, Vol. 406	
/RS/	26	MOGUES, T., et al., "The Relative Importance of T Cell Subsets in Immunity and Immunopathology of Airborn Mycobacterium tuberculosis Infection in Mice"; J. Exp. Med., Feb. 2001, pp. 271-280, Vol. 193, No. 3.	
/RS/	27	MOREIRA A.L. et al., "Mycobacterial Antigens Exacerbate Disease Manifestations in Mycobacterium tuberculosis-infected Mice": Infection and Immunity, Apr. 2002, pp 2100-07, Vol. 70, No. 4.	
/RS/	28	PAVELKA, JR., M.S. and JACOBS, JR., W.R., "Comparison of the Construction of Unmarked Deletion Mutations in Mycobacterium megnants. Mycobacterium brovie, Bacillis Calmette-Seivrin, and Mycobacterium uberculosis H37Rv by Alletic Exchange", Journal of Bacteriology, Aug. 1999, pp. 4780-89, Vol. 181, No. 18.	
/RS/	29	SAMBANDAMURTHY V.K. et al., "A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis"; Nature Medicine, Oct. 2002, pp. 1171-74, Vol. 8, No. 10.	
/RS/	30	SAMBANDAMURTHY V.K. et al., "Long-Term Protection against Tuberculosis following Vaccination with a Severely Attenuated Double Lysine and Pantothenate Auxotroph of Mycobacterium tuberculosis"; infection and Immunity, Feb. 2005, pp. 1196-203, Vol. 73, No. 2.	
/RS/	31	SAMPSON S.L. et al., "Protection Elicited by a Double Leucine and Pantothenate Auxotroph of Mycobacterium tuberculosis in Guinea Pigs"; Infection and Immunity, May 2004, pp. 3031-37, Vol. 72, No. 5.	
/RS/	32	SKINNER M.A. et al., "A DNA prime-live vaccine boost strategy ir mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculests"; Immunology, Apr. 2003, pp. 548-55, Vol. 109, No. 4.	
/RS/	33	SLYSHENKOV, V.S., et al., "Pantothenic Acid and Its Derivatives Protect Eirflich Ascites Tumor Cells Against Lipid Peroxidation"; Free Radical Biology & Medicine, 1995, pp. 767-72, Vol. 19, No. 6.	
/RS/	34	SMITH, D.A., et al. "Characterization of Auxotrophic Mutants of Mycobacterium tuberculosis and Their Potential as Vaccine Candidates"; Infection and Immunity, Feb. 2001, pp. 1142-50, Vol. 59, No. 2.	

Examiner Signature /Rodney Swartz/ Date O3/30/2008 Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{1.} Againaris, unique citation designation number (optional), 2. Againaris is to place a cheak mask here if English Isongaape Transitation is attached.
This collection of Internations in required by 37 CFR 1 Sit. The information is required to to obtain or relate in benefit by the public which is to file (end by the USPTO to process) an application. Confidentiality is governed by 35 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete dispetation from the the USPTO. Time will vary depending upon the individual case. Any comments on the dispetation of the USPTO. Time will vary depending upon the individual case. Any comments on the USPTO. Time will vary depending upon the individual case. Any comments on the USPTO. Time will vary depending upon the individual case. Any comments on the USPTO. Time will vary depending upon the individual case. Any comments on the USPTO. T

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/542 958 Filing Date INFORMATION DISCLOSURE January 23, 2004 (I.A.) STATEMENT BY APPLICANT First Named Inventor William R. Jacobs, Jr. Art Unit not yet determined 1645 (Use as many sheets as necessary) Examiner Name not yet determined Swartz Attorney Docket Number 5 96700/1031 Sheet of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/RS/	35	TAYLOR, J.L., et al., "Pulmonary Necrosis Resulting from DNA Vaccination against Tuberculosis"; Infection and Immunity, Apr. 2003, pp. 2192-98, Vol. 71, No. 4.	
/RS/	36	WEBER, I., et al., "Anaerobic nitrate reductase (narGHJI) activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice"; Molecular Microbiology, 2000, pp. 1017-25, Vol. 35, No. 5.	
·			

Examiner Signature	/Rodney Swartz/	Date Considered	03/30/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Againant's unique distinct designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of Information is required by 37 CFR 1.88. The information is required in a bearted by the public which is to 196 (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is detinated to take 2 hours to complete, including application, and submitting the completed application from the but SPTO. Time will very depending upon the individual case, hondred in the completed application from the but SPTO. Time will very depending upon the individual case, hondred in the completed application from the USPTO. Time will very depending upon the individual case, hondred in the completed application from the but SPTO. Time will very depending upon the individual case, hondred in the completed application of the completed application from the USPTO. Time will very depending upon the individual case, hondred in the complete application of the complete application of the complete application of the complete application. The complete application of th